Inventiva S.A. (IVEVF)

3.6400 0.0000 (0.00%) At close: 04:46PM EDT

Inventiva S.A.

50 rue de Dijon
Daix 21121
France
33 3 80 44 75 00
https://www.inventivapharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 120

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Pierre Broqua Ph.D.	Co-Founder, Chief Scientific Officer, Deputy CEO & Director	439.12k	N/A	1962
Mr. Frederic Cren	Co-Founder, CEO & Chairman	535.77k	N/A	1966
Mr. Jean Volatier	Deputy GM & CFO	N/A	N/A	1965
Ms. Alice Roudot-Ketelers Pharm.D.	Chief Operating Officer	N/A	N/A	1971
Mr. Eric Duranson L.L.M.	General Counsel	N/A	N/A	1974
Ms. Nathalie Harroy	Head of Human Resources	N/A	N/A	1967
Dr. Michael Cooreman	Chief Medical Officer	N/A	N/A	1958
Ms. Pascaline Clerc Ph.D.	Executive Vice President of Strategy & Corporate Affairs	N/A	N/A	1980

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Corporate Governance

Inventiva S.A.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 9; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.